BMY - Bristol-Myers Squibb Company
| Previous Close | 61.28 |
| Open | 61.03 |
| Bid | 62.20 x 3000 |
| Ask | 62.08 x 800 |
| Day's Range | 60.93 - 62.37 |
| 52 Week Range | 42.48 - 62.37 |
| Volume | 17,809,154 |
| Avg. Volume | 16,282,284 |
| Market Cap | 146B |
| Beta (3Y Monthly) | 0.68 |
| PE Ratio (TTM) | 17.95 |
| EPS (TTM) | 3.46 |
| Earnings Date | Jan 22, 2020 - Jan 27, 2020 |
| Forward Dividend & Yield | 1.80 (2.94%) |
| Ex-Dividend Date | 2020-01-02 |
| 1y Target Est | 64.70 |
- Zacks
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $62.09, marking a +1.32% move from the previous day.
- MarketWatch
Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting
A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.
- Zacks
Biotech ETFs Hit New Highs on Deal Activities
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
- Zacks
Fate (FATE) Announces Encouraging Data on Immunotherapies
Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.
- Zacks
Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio
Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.
- Zacks
Zacks.com featured highlights include: Bristol-Myers Squibb, Alaska Air, United Technologies, Synopsys and American Water Works Company
Zacks.com featured highlights include: Bristol-Myers Squibb, Alaska Air, United Technologies, Synopsys and American Water Works Company
- Benzinga
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
- Business Wire
Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001
BRISTOL-MYERS SQUIBB PRESENTS OVERALL SURVIVAL AND SAFETY DATA FROM PIVOTAL CC-486 STUDY QUAZAR AML-001
- Reuters
Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study
Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments. The lowest dose of the therapy, bb21217, had a median duration of response of 11.1 months and an overall response rate of 83% in heavily pre-treated patients with at least three prior lines of therapy, according to data presented at the American Society of Hematology Conference. Bb21217 belongs to a class of drugs called CAR-T therapies that involve drawing white blood cells from a patient, processing them to target cancer cells, and infusing them back into the patient.
- Business Wire
Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
Reblozyl Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
- Zacks
bluebird Reports Positive Top-Line Data on Myeloma Drug
bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.
- Zacks
Top Analyst Reports for Berkshire Hathaway, Verizon & Accenture
Top Analyst Reports for Berkshire Hathaway, Verizon & Accenture
- Zacks
Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio
Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.
- Zacks
Bristol-Myers' (BMY) Lymphoma Drug Meets Goals in Key Study
Bristol-Myers' (BMY) TRANSCEND NHL 001 study on CAR T-cell therapy drug meets endpoints.
- Barrons.com
Bluebird Bio Stock Is Rising on Promising Cancer-Drug Data
Shares took off Monday morning after the company reported data at a medical conference over the weekend that relieved investor anxiety over the company’s experimental cancer drug ide-cel.
- Zacks
Buy These 5 Stocks With Attractive Sales Growth Right Now
Sales growth is an important indicator of a company's health and ability to sustain its business.
- TheStreet.com
Bristol-Myers Jumps After Celgene-Acquired Cancer Treatment Shows Promise
Bristol-Myers shares edged higher Monday after the group said a new cancer treatment, which it acquired through its $74 billion takeover of Celgene Corp., had solid results from an early clinical trial. Bristol-Myers said a study presented to the American Society of Hematology Conference in Orlando, Florida showed a 53% complete response rate for patients with relapsed or refractory large B-cell lymphoma treated with liso-cel. The new treatment, a so-called chimeric antigen receptor T-cell, or " CAR-T" therapy, was acquired from the immunotherapy portfolio of Celgene last year.
- Business Wire
Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting
Studies Evaluating Liso-Cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology
- Business Wire
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
- Business Wire
Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study
BRISTOL-MYERS SQUIBB ANNOUNCES LISO-CEL MET PRIMARY AND SECONDARY ENDPOINTS IN TRANSCEND NHL 001 STUDY
- Reuters
Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal
Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial. The company said it will apply for U.S. approval for the treatment for a type of advanced blood cancer by the end of the year. The treatment, liso-cel, is a newer type of immunotherapy known as CAR-T cell therapy, that takes immune cells from a patient, engineers them to better recognize and attack cancer and infuses them back into the patient.
- Benzinga
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
- Reuters
UPDATE 1-Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial
Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study. The study evaluated the efficacy and safety of the therapy, Ide-cel, in patients who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, the companies said. The therapy belongs to a class of drugs known as chimeric antigen receptor T-cell therapy or CAR-T, which involves drawing white blood cells from a patient, processing them in the lab to target cancer, and infusing the cells back into the patient.
- Bloomberg
Bluebird, Celgene Cancer Therapy Gets Boost From New Study
(Bloomberg) -- An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study, clearing a hurdle in its path to U.S. approval.A single high-dose infusion of the personalized medicine known as bb2121 generated a response in 44 of 54 patients with multiple myeloma, including 19 who had a complete response, the companies said in a statement Friday. Patients went a median of 11.3 months before the cancer progressed, topping expectations that it needed to stop the disease for at least six months to gain approval from the U.S. Food and Drug Administration.Bluebird shares briefly jumped in late trading on Friday before surrendering most of their gains. The recently-issued CVR given in connection with the closing of Bristol-Myers’ deal with Celgene, known by the ticker BMY-R, rose 8.3%.The companies divulged the findings on the eve of the American Society of Hematology’s annual meeting in Orlando, Florida, where GlaxoSmithKline Plc., Regeneron Pharmaceuticals Inc. and Bristol’s own Celgene unit will present data on competing approaches. Cambridge, Massachusetts-based Bluebird and New York-based Bristol-Myers are scheduled to give an update on their next-generation therapy, bb21217, on Monday, while hotly anticipated results from competitor Johnson & Johnson’s Nanjing Legend Biotech-partnered therapy will take the spotlight that morning.The depth and the durability of the data “puts us in very good stead around any of the antibodies as well as other gene therapies,” Bluebird Chief Executive Officer Nick Leschly said. “We feel quite good about it, and that’s why we’re sprinting toward submission and driving toward earlier lines of therapy.”Positive results from the study, dubbed KarMMa, could lead to the first approval of the approach called CAR-T for patients with multiple myeloma, a deadly form of cancer found in white blood cells, wrote Raju Prasad, an analyst at William Blair, in a note. A response rate greater than 80% that can hold off the disease for at least 11 months would be well-received by doctors who might otherwise be wary of potential high costs and an aggressive approach, said Yaron Werber, an analyst at Cowen & Co.The approach known as CAR-T is already approved for a hard-to-treat form of pediatric leukemia and diffuse large B cell lymphoma, both blood cancers that are much less common than the multiple myeloma, which is diagnosed in about 30,000 Americans each year. Bluebird and Bristol’s therapy involves removing infection-fighting T cells from the blood, altering them to recognize a protein known as BCMA that is found in multiple myeloma cells, then putting them back into the patient to kill the cancer.(Updates with stock-price movement in third paragraph)\--With assistance from Tatiana Darie.To contact the reporters on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.net;Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Mark Schoifet, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Business Wire
Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
BMS and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
